Catalyst Event
AbbVie Inc (ABBV) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
3/17/2026, 12:00:00 AM
The FDA rejected Aldeyra Therapeutics' dry eye disease drug, reproxalap, for which AbbVie holds an exclusive commercialization option, citing a lack of substantial evidence of efficacy.
Korean Translation
AbbVie가 독점 상업화 옵션을 보유한 Aldeyra Therapeutics의 안구건조증 치료제 레프록살랍이 효능에 대한 실질적인 증거 부족을 이유로 FDA의 승인을 받지 못함.
Related Recent Events
Mondelez International Inc (MDLZ) · Earnings Release
Analysts estimate Q1 2026 earnings release scheduled for May 5, 2026, estimated.
5/5/2026, 12:00:00 AM
T. Rowe Price Group Inc (TROW) · Earnings Release
Q1 2026 earnings release is scheduled. Importance is estimated as Medium as earnings reports often cause price volatility, scheduled.
5/1/2026, 12:00:00 AM
Conocophillips (COP) · Earnings Release
First quarter 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
MetLife Inc (MET) · Earnings Release
Market impact is estimated to be Low as the date announcement itself has limited effect, but MetLife Inc. is scheduled to release its first-quarter 2026 earnings results on April 30, 2026, scheduled.
4/30/2026, 12:00:00 AM
Automatic Data Processing Inc (ADP) · Earnings Release
Automatic Data Processing is estimated to report its Q3 2026 earnings on or around April 29, 2026, based on past reporting schedules. As earnings reports typically trigger price movements of 5-10%, importance is estimated as Medium, scheduled.
4/29/2026, 12:00:00 AM
United Parcel Service Inc (UPS) · Earnings Release
Q1 2026 earnings release and conference call scheduled for 2026-04-28. Best estimate for importance is Medium, as it will provide the first update on the company's major 2026 restructuring plan, scheduled.
4/28/2026, 12:00:00 AM